We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+32.03%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$977M
AUM Growth
+$222M
Cap. Flow
+$54.3M
Cap. Flow %
5.56%
Top 10 Hldgs %
75%
Holding
45
New
5
Increased
5
Reduced
5
Closed
3

Top Buys

Rank Stock Value
1
SVA
Sinovac Biotech, Ltd
SVA
+$38.2M
2
CDTX
Cidara Therapeutics
CDTX
+$15.1M
3
AKRO
Akero Therapeutics
AKRO
+$10.6M
4
DBVT
DBV Technologies
DBVT
+$9.33M
5
CTMX icon
CytomX Therapeutics
CTMX
+$9.3M

Top Sells

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$37.4M
2
TIL icon
Instil Bio
TIL
+$6.12M
3
RGLS
Regulus Therapeutics
RGLS
+$4.72M
4
VRNA
Verona Pharma
VRNA
+$3.36M
5
DCTH icon
Delcath Systems
DCTH
+$2.52M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLNO
1
DELISTED
Soleno Therapeutics
SLNO
$332M 33.94%
3,958,294
-500,000
-11% -$37.4M
VRNA
2
DELISTED
Verona Pharma
VRNA
$132M 13.49%
1,393,432
-45,353
-3% -$3.36M
CDTX
3
DELISTED
Cidara Therapeutics
CDTX
$63.9M 6.54%
1,311,425
+627,149
+92% +$15.1M
GERN icon
4
Geron
GERN
$937M
$38.4M 3.93%
27,225,292
– –
SVA
5
DELISTED
Sinovac Biotech, Ltd
SVA
$38.2M 3.91%
+5,903,000
New +$38.2M
ORIC icon
6
Oric Pharmaceuticals
ORIC
$1.23B
$31.7M 3.25%
3,126,604
+1,046,154
+50% +$7.02M
TERN
7
DELISTED
Terns Pharmaceuticals
TERN
$25.7M 2.63%
6,895,746
– –
TRVI icon
8
Trevi Therapeutics
TRVI
$2.6B
$24.5M 2.51%
4,487,903
+1,000,000
+29% +$6.22M
AVDL
9
DELISTED
Avadel Pharmaceuticals
AVDL
$23.8M 2.43%
2,684,109
– –
AKRO
10
DELISTED
Akero Therapeutics
AKRO
$23.2M 2.37%
434,689
+233,521
+116% +$10.6M
CMPX icon
11
Compass Therapeutics
CMPX
$364M
$15.7M 1.61%
6,043,466
+2,487,443
+70% +$5.13M
VRDN icon
12
Viridian Therapeutics
VRDN
$2.15B
$13.7M 1.41%
982,576
– –
CTMX icon
13
CytomX Therapeutics
CTMX
$692M
$13.1M 1.34%
+5,769,230
New +$9.3M
ACRS icon
14
Aclaris Therapeutics
ACRS
$743M
$12.6M 1.29%
8,888,888
– –
ZBIO
15
Zenas BioPharma
ZBIO
$2.03B
$11.5M 1.17%
1,183,260
– –
DYN icon
16
Dyne Therapeutics
DYN
$4.27B
$10.6M 1.09%
1,114,960
– –
ABEO icon
17
Abeona Therapeutics
ABEO
$341M
$10.5M 1.07%
1,842,751
– –
DBVT
18
DBV Technologies
DBVT
$805M
$9.66M 0.99%
+1,054,506
New +$9.33M
TRML
19
DELISTED
Tourmaline Bio
TRML
$9.46M 0.97%
591,882
– –
RZLT icon
20
Rezolute
RZLT
$468M
$9.42M 0.96%
2,112,432
– –
CMPS
21
Compass Pathways
CMPS
$1.46B
$9.41M 0.96%
3,362,385
– –
CRVS icon
22
Corvus Pharmaceuticals
CRVS
$1.1B
$8.94M 0.91%
2,234,566
– –
ERAS icon
23
Erasca
ERAS
$6.3B
$8.58M 0.88%
6,756,756
– –
IOBT
24
DELISTED
IO Biotech
IOBT
$8.58M 0.88%
6,173,439
– –
ATXS
25
DELISTED
Astria Therapeutics
ATXS
$8.32M 0.85%
1,552,685
– –
1
2

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.2B AUM 35.94% 1-Year Est. Return
RCYC
Richard C. Young & Co Newport, Rhode Island $1.21B AUM 38.41% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
HCM
Hodges Capital Management Dallas, Texas $1.21B AUM 49% 1-Year Est. Return

Vivo Capital's Q2 2025 Portfolio in Review

As of Q2 2025, Vivo Capital held 45 positions worth $977M, up 29% from $755M the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Vivo Capital deployed $54.3M of net new capital in Q2 2025, opening 5 new positions and adding to 5 existing holdings. Its largest new stake was Sinovac Biotech, Ltd: 5,903,000 shares worth $38.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Soleno Therapeutics, an estimated $37.4M trimmed.

  • Vivo Capital's largest Q2 2025 buy was Sinovac Biotech, Ltd: 5,903,000 shares worth $38.2M.
  • Vivo Capital added most to Cidara Therapeutics in Q2 2025, an estimated $15.1M increase.
  • Vivo Capital's biggest Q2 2025 reduction was Soleno Therapeutics, cutting an estimated $37.4M.
  • Vivo Capital fully exited Regulus Therapeutics in Q2 2025, selling an estimated $4.72M.
  • Vivo Capital's ten largest holdings make up 75% of its $977M portfolio in Q2 2025.
  • Vivo Capital opened 5 new positions and closed 3 in Q2 2025.
  • Vivo Capital's portfolio value rose 29% quarter-over-quarter to $977M.

Based on Vivo Capital's 13F filing for Q2 2025, filed 14 Aug 2025.